Swiss drugmaker Novartis is "completely committed" to its $10 billion-per-year Sandoz generics business, a spokesman said on Thursday, after a newspaper reported Chief Executive Vas Narasimhan plans to split the unit off.


10


Reuters

19 Related Articles from 2018-11-15